Search Results

Locana, Inc., a leading RNA-targeting gene therapy company, announced the appointment of Micah Mackison, as Chief Business Officer.

Locana, a leading RNA-targeting gene therapy company, today announced the appointment of Kathie M. Bishop, Ph.D. as chief scientific officer.

San Diego-based Locana will develop RNA-targeting gene therapy programs.

The Muscular Dystrophy Association and Locana, a leading RNA-targeting gene therapy company, announced the award of an MDA Venture Philanthropy grant totaling $550,000 to advance Locana’s development program for myotonic dystrophy.

Proposed Acquisition Valued at Approximately $15 Million Would Add an Established 50-State Telehealth Business, with over 90,000 clients, Focused on Peptides such as GLP-1 Weight Management, Hormone Health, Longevity and Sexual Wellness Key Highlights: • Target generated approximately $12.7 million in revenue for the trailing twelve months ended August 2026 (unaudited, as provided by Target management) and is cash-flow positive • Proposed purchase price of approximately $15 million, payable in cash and KALA stock; the cash portion is expected to be funded from existing balance sheet resources • Founded in 2023; LegitScript-certified, NABP-accredited platform serving clients in all 50 states; more than 90,000 clients served since inception • 45-day due diligence period expected to conclude in November 2026; definitive agreements and closing targeted for late 2026 or early 2027

Locana, Inc. announced the close of a $55 million Series A financing led by ARCH Venture Partners with participation from Temasek and Lightstone Ventures, all existing investors.